By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Revance Therapeutics, Inc. 

7555 Gateway Boulevard

Newark  California  94560  U.S.A.
Phone: 510-742-3400 Fax: 510-742-3401


Revance is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. The company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented TransMTS® peptide delivery system to address unmet needs in the large and growing neurotoxin markets. Revance's proprietary TransMTS technology enables delivery of botulinum toxin A through two novel drug product candidates, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. Revance is pursuing clinical development for drug product candidates topical RT001 and injectable RT002 in a broad spectrum of aesthetic and therapeutic indications. The company holds worldwide rights for all indications of RT001, RT002 and the TransMTS technology platform.

Key Statistics

Ownership: Public

Web Site: Revance Therapeutics
Employees: 50-100
Symbol: RVNC

Company News
Revance Therapeutics (RVNC) To Present In The 27th Annual Piper Jaffray Healthcare Conference 11/20/2015 8:03:33 AM
Revance Therapeutics (RVNC) Releases Third Quarter 2015 Results 11/10/2015 7:58:19 AM
Revance Therapeutics (RVNC) Announces Closing Of Public Offering Of Common Stock 11/9/2015 10:17:32 AM
Revance Therapeutics (RVNC) To Present At Credit Suisse 24th Annual Healthcare Conference 11/5/2015 10:41:07 AM
Revance Therapeutics (RVNC) To Release Third Quarter 2015 Financial Results Monday, November 9, 2015 11/5/2015 10:13:11 AM
Revance Therapeutics (RVNC) Announces Pricing Of Public Offering Of Common Stock 11/4/2015 7:12:24 AM
Revance Therapeutics (RVNC) Announces Proposed Public Offering Of Common Stock 11/2/2015 7:37:20 AM
Revance Therapeutics (RVNC) Reports Positive 6-Month Duration in BELMONT Study 10/29/2015 10:39:56 AM
Revance Therapeutics (RVNC) Initiates Phase II Clinical Study Of Its Unique Botulinum Toxin Type A For Injection To Treat Cervical Dystonia 9/30/2015 7:05:12 AM
Revance Therapeutics (RVNC) Initiates Phase III Clinical Trial Of Botulinum Toxin Type A Topical Gel To Treat Lateral Canthal Lines 9/29/2015 6:49:41 AM